This study investigated a gene called ID1 (Inhibitor of DNA Binding 1) in clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer, accounting for about 75% of all kidney cancer deaths.
Researchers wanted to understand why some kidney cancers worsen faster than others, and whether a specific gene could serve as a warning sign of how the disease will progress. They focused on the difference between low-grade (less aggressive) and high-grade (more aggressive) tumors.
The team used publicly available cancer databases and computer-based analysis tools to study gene activity patterns and link them to patient outcomes, rather than conducting traditional lab experiments alone.
The study began with gene expression data from 62 differentially expressed genes (DEGs), meaning genes that behaved differently between low-grade and high-grade kidney tumors, drawn from the GEO database (GSE68417) which contains genomic profiles from 49 patient samples.
Researchers then created a protein-protein interaction (PPI) network using the STRING database and visualized it with Cytoscape software. This network maps how proteins in the cell communicate and work together, helping identify which proteins play the most central roles.
From all the genes studied, only ID1 showed a statistically significant difference between low-grade and high-grade ccRCC in the larger TCGA (The Cancer Genome Atlas) dataset of 537 patients, making it the strongest candidate biomarker.
Patients with low ID1 expression in their tumors had significantly worse outcomes. This included shorter overall survival, a higher likelihood of cancer spreading to other organs (metastasis), and higher levels of serum calcium in their blood.
Elevated serum calcium (hypercalcemia) is a known complication of kidney cancer and can cause fatigue, confusion, and kidney damage. Its association with low ID1 suggests that the ID1 gene may play a role in controlling calcium-related pathways in the body.
ID1 encodes a protein that normally prevents certain DNA-binding proteins from being overactive. When ID1 levels are low, this brake on gene activity is lifted, which may allow cancer cells to grow, invade, and spread more freely.
Using the TIMER (Tumor Immune Estimation Resource) tool, researchers analyzed how immune cells infiltrate kidney tumors and how this relates to patient survival. They found that two immune cell types were particularly important.
CD8+ T cells are a type of immune cell that directly attacks cancer cells. Higher levels of CD8+ T cells in the tumor were associated with better outcomes, suggesting an active immune response is beneficial in ccRCC.
Macrophages, another type of immune cell, were also identified as an independent prognostic factor. Depending on how macrophages are activated in the tumor environment, they can either help fight cancer or inadvertently support tumor growth.
The research team searched the Comparative Toxicogenomics Database (CTD), a database that links chemicals and drugs to gene activity, to find compounds that could increase ID1 expression in tumor cells.
Valproic acid emerged as the top candidate drug, ranking highest for its number of documented connections to increasing ID1 activity. Valproic acid is already used clinically as an anti-seizure medication and mood stabilizer, meaning its safety profile in humans is well established.
Repurposing existing drugs for cancer treatment is an active area of research because these medications have already passed many safety trials. This finding suggests valproic acid may deserve further investigation as a treatment to slow kidney cancer progression by boosting ID1 levels.
This study provides a new way to identify which kidney cancer patients are at higher risk of disease progression early in their diagnosis. Testing ID1 expression levels in a tumor biopsy could help doctors predict outcomes and tailor treatment plans accordingly.
The connection between ID1 and the immune environment means this gene may also be relevant for understanding how patients respond to immunotherapy, a treatment that harnesses the immune system to fight cancer.
While the findings are based on database analysis and require validation in clinical trials, they open a promising path toward more personalized kidney cancer care, including the possible use of valproic acid as a targeted supportive treatment.